Your browser is no longer supported. Please, upgrade your browser.
PRQR ProQR Therapeutics N.V. daily Stock Chart
PRQR [NASD]
ProQR Therapeutics N.V.
Index- P/E- EPS (ttm)-1.41 Insider Own8.87% Shs Outstand48.43M Perf Week-1.17%
Market Cap409.72M Forward P/E- EPS next Y-1.63 Insider Trans0.00% Shs Float43.75M Perf Month2.79%
Income-54.80M PEG- EPS next Q-0.38 Inst Own76.30% Short Float1.67% Perf Quarter10.01%
Sales3.10M P/S132.17 EPS this Y37.00% Inst Trans32.92% Short Ratio2.73 Perf Half Y4.19%
Book/sh1.66 P/B5.10 EPS next Y-11.30% ROA-53.10% Target Price27.37 Perf Year-32.59%
Cash/sh1.66 P/C5.08 EPS next 5Y- ROE-66.80% 52W Range5.49 - 16.07 Perf YTD-14.63%
Dividend- P/FCF- EPS past 5Y-47.50% ROI-35.50% 52W High-51.88% Beta0.62
Dividend %- Quick Ratio7.00 Sales past 5Y118.40% Gross Margin- 52W Low40.80% ATR0.50
Employees119 Current Ratio7.00 Sales Q/Q-83.30% Oper. Margin- RSI (14)40.63 Volatility6.87% 5.87%
OptionableYes Debt/Eq0.18 EPS Q/Q-74.60% Profit Margin- Rel Volume1.04 Prev Close8.46
ShortableYes LT Debt/Eq0.17 EarningsMar 04 BMO Payout- Avg Volume267.89K Price7.73
Recom1.70 SMA20-4.84% SMA50-11.48% SMA200-9.72% Volume180,966 Change-8.63%
Mar-12-19Reiterated Chardan Capital Markets Buy $21 → $25
Dec-19-18Initiated RBC Capital Mkts Outperform
Nov-15-18Initiated Citigroup Buy $32
Sep-19-18Initiated Evercore ISI Outperform
Sep-26-17Reiterated JMP Securities Mkt Outperform $14 → $20
Jun-20-16Initiated Chardan Capital Markets Neutral $4.50
Oct-15-14Initiated Deutsche Bank Buy $32
Oct-13-14Initiated H.C. Wainwright Buy $40
Feb-24-20 07:00AM  ProQR to Present at Cowen and Company 40th Annual Health Care Conference GlobeNewswire -6.42%
Feb-06-20 07:00AM  ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases GlobeNewswire +10.51%
Jan-30-20 07:00AM  ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a GlobeNewswire -7.47%
Jan-21-20 04:09AM  3 Healthcare Stocks That Can Double in the Next Year TipRanks +5.35%
Jan-06-20 09:45AM  Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101 Zacks
Dec-23-19 11:51AM  Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 119%? Simply Wall St. +6.33%
Dec-17-19 05:20PM  Did Hedge Funds Drop The Ball On ProQR Therapeutics NV (PRQR) ? Insider Monkey -8.75%
Dec-12-19 03:19PM  ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study Zacks +10.89%
Dec-11-19 02:42PM  Vertex's Kalydeco Gets EU Approval to Treat CF in Infants Zacks
07:00AM  ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa GlobeNewswire
Nov-21-19 08:25AM  ProQR shares rises on FDA orphan drug designation MarketWatch +6.37%
07:00AM  ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa GlobeNewswire
Nov-18-19 07:23AM  ProQR to Present at Upcoming Scientific Conferences GlobeNewswire -9.29%
Nov-13-19 07:00AM  ProQR to Present at Upcoming Investor Conferences GlobeNewswire +5.39%
Nov-06-19 06:09PM  Were Hedge Funds Right About Dumping ProQR Therapeutics NV (PRQR)? Insider Monkey
11:24AM  Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates Zacks
08:55AM  ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:00AM  ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019 GlobeNewswire
Nov-05-19 11:45AM  Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates Zacks
Oct-24-19 12:50PM  BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3 Zacks
Oct-23-19 07:42AM  Will ProQR Therapeutics Continue to Surge Higher? Zacks
Oct-18-19 08:20AM  ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -5.01%
Oct-16-19 07:06AM  The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch Benzinga
Oct-15-19 11:17PM  ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares GlobeNewswire
04:13PM  ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares GlobeNewswire
04:08PM  ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10 GlobeNewswire
Oct-10-19 07:31AM  The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO Benzinga
06:00AM  ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients GlobeNewswire
Oct-07-19 07:00AM  ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO GlobeNewswire
Oct-01-19 09:09AM  ProQR Therapeutics Enters Oversold Territory Zacks
Sep-30-19 07:00AM  ProQR to Present at Two Investor Conferences in October GlobeNewswire -7.10%
Sep-24-19 10:33AM  Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt? Simply Wall St.
Sep-13-19 11:08AM  Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland Zacks
Sep-09-19 07:00AM  ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa GlobeNewswire
Aug-14-19 12:18PM  Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study Zacks -8.05%
Aug-13-19 11:53AM  Mallinckrodt Enrolls First Patient in Liver Disease Study Zacks
Aug-12-19 07:00AM  ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) GlobeNewswire
Aug-07-19 10:05AM  ProQR (PRQR) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:00AM  ProQR Announces Financial Results for the Second Quarter of 2019 GlobeNewswire
Jul-29-19 07:00AM  European Medicines Agency Grants PRIME Access to ProQRs Sepofarsen for Lebers Congenital Amaurosis 10 GlobeNewswire
Jul-26-19 01:31PM  What Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Take Home Last Year? Simply Wall St.
Jul-02-19 07:00AM  ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July GlobeNewswire
Jun-29-19 05:34PM  Heres What Hedge Funds Think About ProQR Therapeutics NV (PRQR) Insider Monkey
Jun-03-19 07:00AM  ProQR to Present at the JMP Securities Life Sciences Conference GlobeNewswire
May-27-19 10:56AM  Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 153%? Simply Wall St.
May-15-19 07:00AM  ProQR to Present at the RBC Capital Markets Healthcare Conference GlobeNewswire
May-08-19 02:29PM  Here is What Hedge Funds Think About ProQR Therapeutics NV (PRQR) Insider Monkey
08:45AM  ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:34AM  ProQR: 1Q Earnings Snapshot Associated Press
07:00AM  ProQR Announces Financial Results for the First Quarter of 2019 GlobeNewswire
Apr-22-19 07:00AM  ProQR to Present at Three Scientific Conferences in April GlobeNewswire
Apr-18-19 07:00AM  ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board GlobeNewswire
07:00AM  ProQR Announces Annual Meeting of Shareholders GlobeNewswire
Apr-16-19 07:26PM  ProQR Initiates Dosing in Phase II/III Eye Disorder Study Zacks -7.38%
Apr-15-19 07:00AM  ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 GlobeNewswire
Apr-01-19 07:00AM  ProQR to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-26-19 04:01PM  ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership GlobeNewswire
Mar-11-19 08:00AM  ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 GlobeNewswire
Mar-05-19 07:00AM  ProQR to Present at Cowen Health Care Conference GlobeNewswire
Feb-28-19 09:50AM  Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus Zacks
Feb-27-19 07:00AM  ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results GlobeNewswire
Feb-21-19 09:34AM  Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer Zacks
Jan-29-19 10:11AM  Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids Zacks
08:30AM  ProQR Announces ProQR Vision 2023 Strategy at its Annual R&D Day GlobeNewswire
Jan-22-19 10:44AM  Should You Worry About ProQR Therapeutics N.V.s (NASDAQ:PRQR) CEO Salary Level? Simply Wall St.
Jan-07-19 07:00AM  ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Lebers Congenital Amaurosis 10 GlobeNewswire
Jan-03-19 09:51AM  Company News For Jan 3, 2019 Zacks
07:00AM  ProQR to Host R&D Day in New York on January 29 GlobeNewswire
Jan-02-19 11:10AM  Best Sector of 2018 and its Hit ETFs & Stocks Zacks +10.77%
07:00AM  ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 GlobeNewswire
Dec-24-18 07:00AM  ProQR Therapeutics Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-23-18 04:31AM  Is ProQR Therapeutics NV (PRQR) Going to Burn These Hedge Funds? Insider Monkey
Dec-17-18 11:52AM  ProQR Announces Publication in Nature Medicine of QR-110 Data for Lebers Congenital Amaurosis 10 GlobeNewswire
Dec-13-18 07:00AM  ProQR Announces Strategic Changes to the Management Team and Key New Hires GlobeNewswire
Dec-10-18 07:00AM  ProQR Receives 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 GlobeNewswire -5.11%
Dec-04-18 07:00AM  ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients GlobeNewswire
Nov-20-18 07:00AM  ProQR to Present at the Evercore ISI HealthConX Conference GlobeNewswire
Nov-16-18 08:55AM  Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-07-18 08:45AM  ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates Zacks -5.23%
07:37AM  ProQR: 3Q Earnings Snapshot Associated Press
07:00AM  ProQR Announces Financial Results for the Third Quarter of 2018 GlobeNewswire
Oct-31-18 07:00AM  ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference GlobeNewswire
Oct-29-18 07:33AM  ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals GlobeNewswire
Oct-16-18 02:39PM  Shareholders Should Check The Ownership Structure Of ProQR Therapeutics NV (NASDAQ:PRQR) Simply Wall St.
Oct-02-18 07:00AM  ProQR to Present at the Chardan Genetic Medicines Conference GlobeNewswire
Sep-24-18 07:00AM  ProQR Announces Presentations at the OTS Annual Meeting GlobeNewswire
Sep-12-18 10:41AM  Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars Zacks -14.35%
Sep-11-18 04:01PM  ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +15.82%
Sep-10-18 04:55PM  Why ProQR Therapeutics N.V. Is Soaring Again Today Motley Fool +18.04%
Sep-08-18 07:16AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Sep-07-18 04:21AM  ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares GlobeNewswire
Sep-06-18 11:20AM  ProQR Up More Than 120% on Favorable Eye Disorder Study Data Zacks -8.26%
08:00AM  Todays Research Reports on Stocks to Watch: ProQR Therapeutics and Sangamo Therapeutics ACCESSWIRE
Sep-05-18 04:01PM  ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares GlobeNewswire +120.75%
12:49PM  Here's Why ProQR Therapeutics N.V. Is Skyrocketing Today Motley Fool
11:20AM  Biotech Stocks & Marijuana Stocks Moving Higher on Wednesday ACCESSWIRE
09:39AM  ProQR's stock rockets to pace all gainers after upbeat drug trial results MarketWatch
09:16AM  ProQR soars as childhood blindness drug succeeds in early trial Reuters
09:15AM  Benzinga Pro's 6 Stocks To Watch Today Benzinga
04:00AM  ProQR drug for rare childhood blindness succeeds in early trial Reuters
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is developing sepofarsen that is in Phase I/II clinical trials for leber's congenital amaurosis; QR-421a and QR-411 for type 2 usher syndrome; QR-1123 for autosomal dominant retinitis pigmentosa; QR-313 for dystrophic epidermolysis bullosa; and Eluforsen for cystic fibrosis. The company's stage pipeline products include QR-504 for fuchs endothelial corneal dystrophy; QR-1011 for stargardt's disease; and QRX-704 for huntington's disease. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center; and partnership agreement with EB Research Partnership and EB Medical Research Foundation. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.